Apoptoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer

Hui Ren,1,2,* Zhihui Chen,1,* Liang Yang,1,2 Weixin Xiong1 Hong Yang3 Kaiwu Xu1 Ertao Zhai1 Li Ding4 Yulong He1,2 Xingming Song1

1Department of Gastrointestinal Surgery Centre, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 2Center for Digestive Disease, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People’s Republic of China; 3Department of Operating Room, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China; 4Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Aim: Identifying high-efficiency prognostic markers for colorectal cancer (CRC) is necessary for clinical practice. Increasing evidence demonstrates that apolipoprotein C1 (APOC1) promotes carcinogenesis in some human cancers. However, the expression status and biological function of APOC1 in CRC remain unclear. Materials and methods: We detected the association between APOC1 expression and clinicopathological features in 140 CRC patients by immunohistochemistry (IHC). High IHC expression of APOC1 was correlated with the N stage, M stage and TNM stage. High IHC APOC1 expression in CRC tissues was associated with poor prognosis. Univariate and multivariate Cox regression analyses showed that APOC1 was an independent risk factor for OS. Cell proliferation of CRC cell lines was inhibited by the downregulation of APOC1. Moreover, si-APOC1 transfection induced cell cycle arrest but low apoptosis increases by regulating the expression of related proteins. Conclusion: APOC1 was overexpressed in CRC tissues, and a high level of APOC1 contributed to a poor prognosis. APOC1 expression influenced the cell proliferation ability and motility capacity of CRC via the MAPK pathway. This work was published in the following Dove Press journal: Cancer Management and Research

Introduction: Colorectal cancer (CRC) is the third most common malignant tumor and is the fourth leading cause of death from cancer worldwide.1,2 The morbidity and mortality of CRC have been increasing in recent years.3 Despite the advance in early detection, chemotherapy, surgery and target therapy, the prognosis of patient with advanced CRC remains poor. CRC development is a multistep process with the accumulation of genetic and epigenetic alterations. Therefore, it is important to...
clarify the molecular mechanisms controlling CRC progression and explore novel targeted drugs for improving the prognosis of CRC patients.

Apolipoprotein C1 (APOC1), a producer gene located at 19q13.32, belongs to the apolipoprotein C family. The protein is mainly synthesized by the liver and other tissues such as the brain, lung, spleen and intestines.4 APOC1 participates in lipoprotein metabolism by regulating the expression of lipase, transferases and cholesteryl ester transfer protein (CETP) and inhibiting the uptake of triglyceride lipoprotein by the hepatic lipoprotein receptor. However, in recent years, some studies have confirmed that APOC1 promotes carcinogenesis and tumor development.5–7 APOC1 is highly expressed in late-stage lung cancer and is likely involved in the progression of the tumor burden. In papillary thyroid carcinoma, APOC1 can be considered a candidate prognostic biomarker for patients with papillary thyroid carcinoma.8 However, the role of APOC1 in CRC progression has not been revealed.

APOC1 is a type of secretory protein commonly associated with very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL).6,10 Recent studies showed that LDL can regulate cell proliferation, migration and apoptosis and induce cell inflammation via MAPK signaling pathways.11–14 MAPK signaling pathways participated in a wide range of complex biologic processes, such as cell proliferation, cell death, cell migration and cell invasion.15–17 MAPKs are a group of serine-threonine kinases that mediate a wide variety of cellular behaviors in response to extracellular stimuli.18 The foremost enzymes studied in the MAPK family include the extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun amino-terminal-kinase 1–3 (JNK 1/2/3) and p38MAPK.

In this study, we first detected APOC1 expression in CRC tissues and analyzed its clinical significance in patients with CRC. Then, we investigated the role of APOC1 on cell proliferation, apoptosis, migration and invasion in CRC cell lines. Furthermore, by analyzing the data from TCGA cohorts, we determined that APOC1-regulated CRC progression by activating the P38 MAPK signaling pathway. Our study demonstrates that APOC1 could be a prognostic factor in CRC.

Materials and methods

Patients and tissue samples

A total of 140 cases of CRC paraffin-embedded samples and 15 paired fresh CRC samples were enrolled in this study. All samples were obtained from CRC patients undergoing colorectal surgery at the Gastroenterology of the First Affiliated Hospital of Sun Yat-sen University (FAHSYSU) in 2010 and 2017. The 140 paraffin-embedded samples were used for immunohistochemistry and histological evaluation. The patient’s demographic and clinicopathological features are shown in Supplemental Table 1. The CRC TNM status was applied according to guidelines from the 2017 American Joint Committee on Cancer staging manual (AJCC 8th edition). All patients had follow-up records of more than 5 years between 2010 and 2017. Survival time was measured from the date of surgery to the follow-up deadline or date of death (usually the result of cancer recurrence or metastasis). Another 15 paired fresh samples obtained in 2017 were used for immunohistochemistry, protein and RNA expression analysis. In addition, no patient received preoperative chemotherapy or radiotherapy. All patients had provided a written informed consent by the First Affiliated Hospital of Sun Yat-sen University Institutional Review Board for the use of these clinical materials for research purposes. And this study was conducted in accordance with the Declaration of Helsinki.

Immunohistochemistry (IHC)

The following procedures were performed by classical biotin–streptavidin–peroxidase IHC staining protocols according to previously described methods.19 Briefly, the protein expression of APOC1 was detected by anti-APOC1 (1:200, ab198288, Abcam Inc, Cambridge, MA, USA) antibody and a goat anti-mouse/rabbit secondary antibody (Gene Tech Co Ltd, GTVisionTM III Detection System/Mo&Rb, Shanghai, China). To estimate the score for the 140 cases of CRC paraffin-embedded samples, five high-power fields were chosen randomly for the assessment of APOC1 expression in a double-blind procedure. The sample scores were based on both the intensity of staining and the proportion of positively stained tumor tissue. The immunostaining results were scored based on the following system: for staining intensity scoring: 0 (negative), 1 (weak), 2 (moderate), 3 (strong); for staining area scoring: 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%) and 4 (76–100%). The staining index was calculated as the product of the proportion of positive tissue × the staining intensity score (range from 0 to 12). An optimal cutoff value was identified as follows: a staining index score ≥6 was considered as tumors with high APOC1 expression and ≤4 was considered as tumors with low expression of APOC1.20
Cell culture and treatment

Human CRC cell lines (SW1116, SW620, HCT116, SW480 and LS174T) were obtained from the American Type Culture Collection (Manassas, VA, USA). NCM460, a human immortalized colonic epithelial cell line, was obtained from IN CELL (San Antonio, TX, USA). All cell lines were cultured at 37°C with 5% CO₂ in DMEM/RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 100 U/mL penicillin and 100 μg/mL streptomycin.

Cell transfection with small interfering RNA (siRNA)

To knock down the expression of APOC1, three APOC1-targeted siRNAs (si-APOC1#1–3) and a negative control siRNA (si-Control) synthesized by GenePharma (RiboBio,
Guangzhou, China) were used. The siRNA sequences are shown in Table S1. SW480 and SW620 cells were transiently transfected with siRNAs using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The transfected cells were designated as SW480/si-APOC1, SW480/si-Control, SW620/si-APOC1 and SW620/si-Control, respectively.

RNA extraction, reverse transcription and real-time quantitative PCR
Total RNA was extracted from cultured cells or tissues using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Real-time quantitative PCR was performed using SYBR Green I (Invitrogen) with an ABI PRISM 7500 system (Applied Biosystems, Foster City, CA, USA). The housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control. Primers for real-time quantitative PCR are summarized in Table S2.

Western blotting
Western blotting was performed as previously described.\textsuperscript{21} The following primary antibodies were used: APOC1 (1:1000, ab198288), cyclin B1 (1:5000, ab32053), cyclin D1 (1:5000, ab134175), caspase-9 (1:1000, ab202068), BCL-2 (1:500, ab32124), ERK1/2 (1:500, ab196883), phospho-ERK1/2 (1:500, ab65142), and GADPH (1:2500, ab9485) were purchased from Abcam Inc. Phospho-p38 (1:1000, #9211), p38 (1:1000, #9212), phospho-JNK (1:1000, #9251) and JNK (1:1000, #9252) were purchased from Cell Signaling Technology (Boston, MA, USA). Goat anti-rabbit IgG H&L (1:2000, ab6721, Abcam) was used as a second antibody.

Cell proliferation detection
Cell proliferation detection was assessed by the Cell Counting Kit-8 (CCK-8) cell proliferation kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions. Briefly, cells were plated into 96-well plates at 2×10^3 cells/well with 100 μL complete medium and cultured under normal conditions. At the indicated times, cells were incubated with 100 μL of RPMI-1640 medium plus 10 μL of CCK8 reagent at 37°C for 2 hrs. Then, the absorbance was measured on a microplate reader (Bio-Rad, La Jolla, CA, USA) at a wavelength of 450 nm. Three independent repeat experiments were performed.

Flow cytometry analysis of the cell cycle and apoptosis
Flow cytometry analysis was performed as previously described.\textsuperscript{22} For cell cycle analysis, the cells were trypsinized and washed into single-cell suspensions and fixed with ice-cold 70% ethanol at −20°C overnight. The fixed cells were then subsequently stained with 20 mg/mL propidium iodide (PI) staining buffer (containing 1% Triton X-100 and 100 mg/mL RNase A) for 30 mins. DNA content was assessed using a FACSCalibur unit (Becton Dickinson, Franklin Lakes, NJ, USA) equipped with ModFit LT v2.0 software. To analyze apoptosis, cultured cells were harvested by trypsinization and were washed with PBS. Cells (1×10^6) from each sample were processed for annexin V-fluorescein isothiocyanate (FITC)/PI apoptosis detection according to the manufacturer’s instructions (Becton Dickinson, Franklin Lakes, NJ, USA). All the experiments were repeated at least three times.

Colony formation assay
Briefly, exponentially growing cells were seeded into 6-well plates (1000 cells/well) and cultured at 37°C with 5% CO\textsubscript{2} for 10–14 days. The colonies were fixed with 75% ethanol for 30 mins and then were stained with 0.5% crystal violet (Beyotime, Nanjing, China) for visualization and counting. Only colonies with more than 50 cells were counted manually. Triple wells were included for each group of cells, and all experiments were repeated three times.

Transwell migration and invasion assays
Cell transwell migration and invasion assays were performed using a transwell apparatus (Corning, NY, USA) with the upper chamber of an 8-μm pore size polycarbonate membrane placed in matched 24-well cell culture plates. For the migration assay, cells (1×10^5) in 200 μL RPMI-1640 were seeded into the upper chamber without Matrigel; for the invasion assay, cells (2×10^5) in 200 μL RPMI-1640 were seeded into the upper chamber with a thin layer of 0.5 mg/L Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). For both assays, 500 μL RPMI-1640 containing 20% FBS was added to the lower chambers. The plates were incubated for 24 hrs (migration) or 48 hrs (invasion). Then, cells that had migrated or invaded to the bottom of the membrane were fixed with 75% methanol for 30 mins and stained with 0.5% crystal violet for 1 hr. Cells were counted in 5 random fields for each membrane under a microscope (Axio Observer Z1,
ZEISS, Germany) at 100× magnification. Each measurement was carried out in triplicate wells, and independent experiments were repeated three times.

**Bioinformatics analysis**

We collected gene expression data for 380 colon and rectal adenocarcinomas (COAD-READ) and 50 normal tissues from The Cancer Genome Atlas website (TCGA, https://tcga-data.nci.nih.gov/tcga/). To investigate the molecular pathways associated with overexpression of APOC1 in CRC, gene set enrichment analysis (GSEA) was performed using the GSEA desktop software. Enriched gene sets comparing APOC1 higher expression and lower expression were identified using 1,000 permutations of the phenotype labels. We also used Oncomine (https://www.oncomine.org), a database of RNA and DNA sequencing information curated from The Cancer Genome Atlas, Gene Expression Omnibus and other published literature to evaluate and compare the expression level of APOC1 between CRC and normal samples.

**Statistical analysis**

The results are expressed as mean±SD. All statistical analyses were performed using the SPSS statistical software package (standard V.20.0; IBM Corporation, Armonk, USA.). Pearson’s Chi-square test was used for comparison of patient clinico-pathological characteristics with APOC1 expression. A Cox regression proportional hazards model was used for univariate and multivariate analyses to determine the independent significance of relevant clinical covariates. The association of APOC1 expression and overall survival (OS) rates of patients were calculated by the Kaplan–Meier method, and differences were analyzed using the log-rank test. Values of P<0.05 in all cases were considered statistically significant.

**Results**

**APOC1 is overexpressed in primary CRC**

To evaluate APOC1 expression in CRC and normal tissues, we first analyzed APOC1 expression in the TCGA cohort (Figure 1A and B). The upregulation of APOC1 mRNA was validated in CRC samples (N=380) compared to normal samples (N=50) from the TCGA cohorts (P=0.012) (Figure 1A). A similar trend was observed in paired tumor and adjacent normal samples in the same cohort (N=25; P=0.002) (Figure 1B). We also found that APOC1 mRNA expression was upregulated in different Oncomine CRC cohorts (Table 2). We then evaluated the mRNA and protein expression levels of APOC1 in 15 paired CRC and adjacent normal fresh samples by qPCR and Western blots. The mRNA levels were significantly elevated in the CRC tissues compared to the matched adjacent normal tissues (P<0.05, Figure 1C). Consistent with these results, the protein expression level of APOC1 in Case 1 to Case 4 was significantly lower in the adjacent normal tissues (N) compared with the matched CRC tissues (T) as shown in Western blots (Figure 1D).

To estimate the relation between APOC1 expression and clinicopathological features, 140 cases of paraffin-embedded samples from patients with CRC were analyzed using immunohistochemistry staining. All patients with CRC were divided into two groups (APOC1 high or low expression) by the cutoff value that was established by immunohistochemistry. APOC1 protein expression was distributed in the cytoplasm of CRC tumor cells, but was negative in normal colon tissue cells (Figure 1E). As shown in Table 1, there was no correlation between APOC1 expression and clinicopathological features such as gender, age, tumor size, differentiation degree and tumor location, while high expression of APOC1 was significantly positively associated with N stage (P=0.05), M stage (P=0.015) and TNM stage (P=0.033). Thereafter, the Kaplan–Meier method was used to determine the effect of APOC1 expression on patient survival. The data showed that patients with high IHC expression of APOC1 had significantly shorter OS than others (P=0.005, log-rank test) (Figure 1F). The disease-free survival (DFS) results were similar (Figure 1G). Moreover, in univariate Cox regression analysis, high expression of APOC1 was significantly associated with poor OS and DSF with a HR of 2.059 (95% CI=1.231 to 3.444; P=0.006; Table 3) and 1.803 (95% CI=1.101 to 2.955; P=0.019; Table S3). After the adjustment for potential confounding factors, multivariate Cox regression analysis showed that high expression of APOC1 might be an independent prognostic factor in CRC (HR=1.704; 95% CI=1.012 to 2.869; P=0.045; Table 3). Thus, these results suggest that APOC1 is highly expressed and upregulated in CRC, and APOC1 may be predictive for clinicopathological significant events for patients with CRC.

**APOC1 is overexpressed in CRC cell lines**

We subsequently examined levels of APOC1 expression in five CRC cell lines (SW1116, SW620, HCT116, SW480...
and LS174T) and a human immortalized colonic epithelial cell line (NCM460) by Western blotting and RT-PCR. Western blotting analysis showed that five CRC cell lines had higher protein levels of APOC1 compared with NCM460 (Figure 2A). Similarly, APOC1 mRNA expression was at least fourfold greater in the CRC cell lines compared with NCM460 (Figure 2A). SW480 and SW620 were selected for the following experiments because of the high mRNA and protein expression levels of APOC1.

To determine the potential functions of APOC1 in CRC, SW480 and SW620 cells were transfected with different APOC1 siRNAs (si-APOC1#1–3) oligomers to knock down endogenous APOC1, and a nonspecific siRNA (si-Control) was used as the negative control. APOC1 mRNA and protein expression levels were downregulated by transfection of APOC1 siRNAs (Figure 2C and D). The si-APOC1#1, which had a higher knockdown efficiency than si-APOC1#2–3, was then used in the following assays.

**Silencing of APOC1 inhibits CRC cell proliferation**

To clarify the role of APOC1 in cell proliferation, CCK-8 assays and clonogenic assays were performed. The results of the CCK-8 assay suggested that the proliferation rate of silenced APOC1 cells was lower than its control cells (both $P<0.05$, Figure 3A). Moreover, a clonogenic assay indicated that, compared with control cells, silenced APOC1 cells showed decreased colony formation capacity after 10–14 of days conventional culture (both $P<0.01$,
Collectively, these results indicated that silencing of APOC1 may inhibit CRC cell proliferation. Silencing of APOC1 induces CRC cell cycle arrest and apoptosis in CRC cells

We next evaluated the effect of APOC1 knockdown on the cell cycle distribution and apoptosis in CRC cells by flow cytometry. As shown in Figure 3C, silencing of APOC1 was associated with cell accumulation in the G0/G1 phase and decreased in the G2/M phase in SW480 and SW620, respectively, compared with the control cells (both \( P < 0.05 \)). Subsequently, an apoptosis assay showed that despite statistical differences, silencing APOC1 does not induce biologically significant changes in apoptosis rate. Further, biochemical markers of the cell cycle and apoptosis were detected. Western blot analyses revealed that protein levels of G1 phase-related cyclin D1 and G2 phase-related cyclins B1

| Table 2 Oncomine analysis of APOC1 expression in colorectal cancer (total 7 colorectal cancer cohorts) |
|---|---|---|---|---|
| Cohort number | Cohort | Sample (n) | Fold-change | \( P \)-value |
| 1 | Notterman Colon \(^1\) | Colon adenocarcinoma (18) vs normal (18) | +7.94 | \( 4.94 \times 10^{-5} \) |
| 2 | Gaspar Colon \(^2\) | Colon adenocarcinoma epithelia (56) vs normal (22) | +1.166 | \( 3.75 \times 10^{-4} \) |
| 3 | Skrzypczak Colorectal \(^3\) | Colon carcinoma (5) vs normal (10) | +1.373 | \( 9.32 \times 10^{-4} \) |
| 4 | | Colon carcinoma epithelia (5) vs normal (10) | +1.551 | \( 1.76 \times 10^{-5} \) |
| 5 | Kaiser Colon \(^4\) | Rectal mucinous adenocarcinoma (4) vs normal (5) | +2.514 | 0.039 |
| 6 | | Cecum adenocarcinoma (17) vs normal (5) | +2.049 | 0.005 |
| 7 | | Rectosigmoid adenocarcinoma (10) vs normal (5) | +1.963 | 0.016 |
| 8 | | Colon adenocarcinoma (41) vs normal (5) | +1.836 | 0.006 |
| 9 | | Colon mucinous adenocarcinoma (13) vs normal (5) | +4.147 | \( 7.09 \times 10^{-4} \) |
| 10 | | Rectal adenocarcinoma (8) vs normal (5) | +2.464 | 0.013 |
| 11 | TCGA Colorectal | Colon mucinous adenocarcinoma (22) vs normal (22) | +2.135 | \( 6.42 \times 10^{-4} \) |
| 12 | | Colon adenocarcinoma (101) vs normal (22) | +1.548 | 0.002 |
| 13 | Hong Colorectal \(^5\) | Colorectal carcinoma (70) vs normal (12) | +2.028 | 0.011 |
| 14 | | Colorectal carcinoma (36) vs normal (24) | +1.399 | 0.035 |

**Notes:** The TNM staging system is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N) and the presence of metastasis. *Statistically significant.

| Table 3 Cox regression analysis of potential overall survival factors for patients with colorectal cancer |
|---|---|---|---|---|
| Variable | Univariate analysis | Multivariate analysis |
| | HR (95% CI) | \( p \)-Value | HR (95% CI) | \( p \)-Value |
| Age (years) | 0.851 (0.515 to 1.408) | 0.531 | 0.081 (0.023 to 0.280) | \(<0.001^*\) |
| Gender | 1.464 (0.885 to 2.423) | 0.138 | 0.909 (0.027 to 0.328) | \(<0.001^*\) |
| Tumor location | 1.080 (0.919 to 1.269) | 0.351 | 0.222 (0.112 to 0.437) | \(<0.001^*\) |
| Tumor size | | | | |
| <5 cm | 0.556 (0.338 to 0.939) | 0.028 * | 0.385 (0.201 to 0.735) | \(<0.001^*\) |
| \( \geq 5 \) cm | 1.000 | | 1.000 | |
| TNM stage | | | | |
| I | 0.081 (0.023 to 0.280) | \(<0.001^*\) | 0.094 (0.027 to 0.328) | \(<0.001^*\) |
| II | 0.208 (0.106 to 0.408) | \(<0.001^*\) | 0.222 (0.112 to 0.437) | \(<0.001^*\) |
| III | 0.377 (0.198 to 0.719) | 0.003 * | 0.385 (0.201 to 0.735) | \(<0.001^*\) |
| IV | 1.000 | | 1.000 | |
| APOC1 expression | | | | |
| High | 2.059 (1.231 to 3.444) | 0.006 * | 1.704 (1.012 to 2.869) | 0.045 * |
| Low | 1.000 | | 1.000 | |

**Notes:** The TNM staging system is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N) and the presence of metastasis. *Statistically significant.
and Bcl-2 were downregulated by silencing of APOC1, while caspase-9 was upregulated (Figure 3F). These results suggested that silencing of APOC1 may induce G0/G1 phase cell cycle arrest and apoptosis in CRC.

Silencing of APOC1 suppresses CRC cell migration and invasion

To determine the effects of APOC1 on cell invasion and migration, transwell assays with or without Matrigel were performed. Transwell assays revealed that silencing of APOC1 in SW480 and SW620 cells led to approximately 20–40% reduction in numbers of migrated and invaded cells compared with si-Control transfected cells (P<0.01 and P<0.05) (Figure 3E). These results indicate that APOC1 protein may be necessary for cell invasion and migration, and silencing of APOC1 can efficiently repress the motility of CRC cells, and more in vivo investigation is needed.

Silencing of APOC1 suppresses the expression of the phosphorylated form of p38 MAPK

To identify the possible APOC1-associated pathways in CRC, GSEA was conducted with data from the TCGA COAD-READ dataset. As illustrated in Figure 4A and B and Figure S1, the heatmap and GSEA enrichment plot showed that APOC1 expression may be associated with extracellular matrix (ECM) receptor interaction and the Toll-like receptor (TLR) signaling pathway and is strongly associated with the mitogen-activated protein kinase (MAPK) signaling pathway.

Based on the above results and other reports, we predicted that APOC1 may promote colorectal carcinogenesis via MAPK signaling pathways. To preliminarily verify this hypothesis, we analyzed MAPK signaling pathway-related proteins in SW480 and SW620 cells at 48 hrs after transfection with or without siRNA by Western blotting. Compared with the blank and si-Control group, the phosphorylated form of p38 MAPK (p-p38) decreased after knockdown of APOC1 protein, whereas no significant changes were observed in phosphorylated-Erk1/2 (p-ERK) and phosphorylated-JNK (p-JNK) (Figure 4C). These results indicated that silencing of APOC1 suppressed p-p38 expression, and APOC1 may be involved in CRC carcinogenesis by activating the p38 MAPK signal pathway.

Discussion

CRC is a biologically heterogeneous disease involving various genetic and epigenetic alterations, and numerous molecular variables that contribute to the occurrence of CRC have been characterized.30,31 In this study, we
identified APOC1 as a potential pro-oncogenic protein involved in cell proliferation, migration and invasion of CRC. Our results indicated that APOC1 mRNA and protein expression is higher in CRC tissues and cell lines than in adjacent normal tissues and immortalized colonic epithelial cell lines. Furthermore, we found that APOC1 plays a potential prognostic role in the survival of CRC patients, highlighting the potential values of APOC1 as an independent prognostic biomarker in human CRC. Mechanistically, we used bioinformatic approaches to analyze the possible pathway. We conjectured that APOC1 promotes cell proliferation, migration and invasion through the p38 MAPK signaling pathway.

Previous studies have demonstrated that APOC1 plays an important role in lipid metabolism-related diseases, such as glomerulosclerosis, cardiovascular disease, diabetes and Alzheimer’s disease. However, emerging evidence suggests that APOC1 might be used as a new biomarker to evaluate the prognosis of patients with malignant tumors. Patients with higher or positive APOC1 expression showed a worse prognosis and advanced tumor progression in patients with pancreatic cancer, gastric cancer, lung cancer and papillary thyroid carcinoma. Our study showed that high APOC1 protein levels were correlated with a higher Duke’s classification, higher T stage, higher N stage, higher M stage and higher TNM stage (Table 1). Survival analysis demonstrated that patients with high APOC1 expression had shorter survival times than those with low expression (Figure 1F–G). These results indicate that APOC1 is an important molecular marker and prognostic factor for solid tumors.

Figure 3 Effects of APOC1 knockdown on the proliferation, apoptosis, migration and invasion of CRC cells after transfection with si-Control or si-APOC1. Notes: (A) Cell proliferation of SW480 and SW620 cells was detected using the CCK-8 assay. (B) Representative images of the clonogenic cell survival assays that were performed in SW480 and SW620 cells. (C) Flow cytometry analysis of the proportion of the cells indicated in each stage of the cell cycle (G1, G2 and S) and the percentage of cells in the G0/G1, S and G2/M phase of the cell cycle were quantified and expressed as the mean ± SD from three independent experiments. (D) Levels of apoptosis in the SW480 and SW620 cells after transfection with si-Control or si-APOC1 for 24 hrs. The cells were stained with Annexin V and PI. (E) Cell migration and invasion in SW480 and SW620 cells were assessed using Transwell assay with or without a Matrigel-coated transwell chamber. Magnification, ×100. (F) Detection of Bcl-2, caspase-9, cyclin D1 and cyclin B1 protein levels by Western blotting. Detection of GAPDH was used as a loading control. Blank: wild-type cells; si-Control: negative control siRNA; si-APOC1: APOC1-siRNA transfected cells (*p<0.05, **p<0.01 Vs si-APOC1).
Engweegen et al.\textsuperscript{38} reported that APOC1 plays a potential role in distinguishing a colon cancer and a healthy control group. Similarly, Yasui et al.\textsuperscript{39} found that compared with normal gastric epithelial cells, APOC1 was upregulated in gastric cancer, as shown by serial analysis of gene expression. Similar to Yasui’s report, our study found that APOC1 was highly expressed and upregulated in primary CRC (Figure 1A–E and Figure 2A–B). Trougakos et al.\textsuperscript{40} indicated that knockdown or silencing of apolipoprotein-J in osteosarcoma and prostate cancer cells can significantly inhibit tumor cell proliferation and promote tumor cell apoptosis. In the present study, we found that silencing of APOC1 may attenuate the CRC cell proliferation rate (Figure 3A) and colony formation capacity (Figure 3B) and suggested that silencing of APOC1 may inhibit the proliferation function in CRC. We also found that silencing of APOC1 arrested CRC cells in the G0/G1 phase by flow cytometry (Figure 3C). Our Western blot results showed that cyclin B1 and cyclin D1 protein level were decreased in APOC1 silenced cells (Figure 3F), and it further confirmed that silencing APOC1 may arrest CRC cells in the G0/G1 phase. Flow cytometry showed that silencing of APOC1 increased CRC cell total apoptosis (Figure 3D) and confirmed the protein levels of caspase-9 and Bcl-2 by Western blotting (Figure 3F). These results suggested that APOC1 may affect cell proliferation of CRC cells by cell cycle arrest and cell apoptosis.

Christine et al.\textsuperscript{41} reported that APOC1 was overexpressed in invasive pancreatic carcinoma, as shown by in situ hybridization and speculated that APOC1 overexpression may increase the invasive function of pancreatic carcinoma. Similarly, silencing of APOC1 may attenuate the migration and invasion functions of CRC cells (Figure 3E). It is suggested that APOC1 may also participate in motility of CRC cells and have a promoting function.

It has been reported that APOC1 could function as a potential tumor oncogene in different cancers.\textsuperscript{5–7} Some reports showed that APOC1 can activate or inhibit some
kinases to regulate physiological or pathological functions, which were correlated with the genesis and development of cancers. However, the mechanism of APOC1 in cancers is not yet elucidated. Takano et al reported that APOC1 can affect preinvasive carcinoma by an autocrine function. In addition, it has been proved that APOC1 secreted as an autocrine was necessary for tumor cell survival and malignant phenotype. Thus, APOC1 may inhibit cells apoptosis to affect tumorigenesis and development. In contrast, a report indicated that APOC1 peptides can inhibit cell proliferation and promote apoptosis in breast cancer cells in vitro and suppress tumor growth in nude mice, but the mechanism was unconfirmed. To explore the molecular mechanism by which APOC1 exerted its functions on CRC, we performed GSEA on the TCGA COAD-READ dataset. GSEA is a bioinformatic approach that can analyze the possible correlation of a target gene and known functional gene sets. GSEA showed that many cancer-related gene sets, including ECM receptor interaction, the TLR pathway and MAPK pathways, were positively correlated with APOC1 expression (Figure 4A and B and Figure S1). Through further analysis, we found that the apolipoprotein family could trigger MAPK signaling pathways to cause cell proliferation, apoptosis and invasion. So, we conjectured that APOC1 may be associated with MAPK signaling pathways in CRC and further validated by immunoblotting (Figure 4C) that knockdown of APOC1 may decrease the phosphorylation of p38 without obviously changing total ERK1/2, p38, JNK1/2/3, phosphorylated-ERK1/2 and phosphorylated-JNK1/2/3. We initially conjectured that silencing APOC1 in CRC may inactivate the p38MAPK pathway to attenuate CRC cell proliferation, migration and invasion. Thus, we conjectured that APOC1 could promote CRC cell proliferation, migration and invasion via the MAPK pathway.

Conclusion
This study demonstrated that APOC1 was overexpressed in CRC tissues and that a high level of APOC1 contributed to a poor prognosis. APOC1 expression influenced the cell proliferation ability and motility capacity of CRC via the MAPK pathway. Our findings suggest that APOC1 could be used as a prognostic biomarker in CRC, although further investigation is needed.

Acknowledgments
This study was supported by grants from the Natural Science Foundation of Guangdong Province (2017A030310194 and 2017A030310215), Science and Technology Planning Project of Guangdong Province (2016A020216008), Medical Scientific Research Foundation of Guangdong Province (A2017267 and A2017274), and Administration of Traditional Chinese Medicine of Guangdong Province, China (20151162).

Author contributions
All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–548.
2. Stewart BW, Wild C. World Cancer Report 2014 [M]. Lyon, France: International Agency for Research on Cancer, 2014:16–53.
3. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.21395
4. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19(3):472–484.
5. Zhang J, Guo F, Wang L, et al. Identification of apolipoprotein C-I as a potential Wilms' tumor marker after excluding inflammatory factors. Int J Mol Sci. 2014;15(9):16186–16195. doi:10.3390/ijms150916186
6. Moore LE, Brennan P, Karami S, et al. Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res. 2009;69(20):8001–8008. doi:10.1158/0008-5472.CAN-09-1734
7. Takano S, Yoshitomi H, Togawa A, et al. Apolipoprotein C-I maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 2008;27(20):2810–2822. doi:10.1038/sj.onc.1210951
8. Fan Y, Shi L, Liu Q, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer. 2009;8:79. doi:10.1186/1476-4598-8-79
9. Jong MC, van Dijk KW, Dahlmans VE, et al. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenosine-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochim J. 1999;338(Pt 2):281–287.
10. Jong MC, Dahlmans VE, van Gorp PJ, et al. In the absence of the low-density-lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996;98(10):2259–2267. doi:10.1172/JCI19036
11. Zhang H, Liang B, Lu T, et al. Oxetin A suppresses oxidized LDL induced endothelial cell inflammation via MAPK p38 and NF-kappaB signaling pathway. IUBMB Life. 2018;70(10):961–968. doi:10.1002/iub.1890
12. Li W, Zhi W, Zhao J, et al. Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-kappaB. Vascul Pharmacol. 2018;108:57–66. doi:10.1016/j.vph.2018.05.005
13. Wang X, Mao R, Chen W. FSD-C10 shows therapeutic effects in suppressing oxidized low-density lipoprotein (ox-LDL)-induced human brain microvascular endothelial cells apoptosis via Rho-Associated Coiled-Coil Kinase (ROCK)/Mitogen-Activated Protein Kinase (MAPK) Signaling. Med Sci Monit. 2018;24:5509–5516. doi:10.12659/MSM.911481
14. Wang S, Zhou H, Feng T, et al. beta-Glucan attenuates inflammatory responses in oxidized LDL-induced THP-1 cells via the p38 MAPK pathway. *Nutr Metab Cardiovasc Dis.* 2014;24(3):248–255. doi:10.1016/j.numecd.2013.09.019

15. Carnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol Mol Biol Rev.* 2011;75(1):50–83. doi:10.1128/MMBR.00031-10

16. Waetzig V, Heredgen T. Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. *Neurosci Lett.* 2004;361(1–3):64–67. doi:10.1016/j.neulet.2004.02.041

17. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. *Science.* 2002;296(5560):1911–1912. doi:10.1126/science.1072682

18. Chen Z, Cobb MH. Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TA2O. *J Biol Chem.* 2001;276(19):16070–16075. doi:10.1074/jbc.M100681200

19. Xu K, Song X, Chen Z, et al. XRC22 promotes colorectal cancer cell growth, regulates cell cycle progression, and apoptosis. *Medicine (Baltimore).* 2014;93(28):e294. doi:10.1097/MD.0000000000000294

20. Li C, Cao L, Xu C, et al. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer. *Hum Pathol.* 2018;75:16–25. doi:10.1016/j.humpath.2017.11.010

21. Xu K, Chen Z, Cui Y, et al. Combined olaparib and oxaliplatin inhibits tumor proliferation and induces GSTM2 arrest and gamma-H2AX foci formation in colorectal cancer. *Onco Targets Ther.* 2015;8:3047–3054. doi:10.2147/OTT.S91954

22. Qin CJ, Song XM, Chen ZH, et al. XRC22 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. *OncoTarget.* 2015;6(31):32193–32204. doi:10.18632/oncotarget.4975

23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102

24. Subramanian A, Kuehn H, Gould J, et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis. *Bioinformatics.* 2007;23(23):3251–3253. doi:10.1093/bioinformatics/btm369

25. Notterman DA, Alon U, Storz AJ, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. *Cancer Res.* 2001;61(7):3124–3130.

26. Gaspar C, Cardoso J, Franken P, et al. Cross-species comparison of human and mouse intestinal polysaccares reveals conserved mechanisms in adenomatous polyposis coli (APC)-driven tumorigenesis. *Am J Pathol.* 2008;172(5):1363–1380. doi:10.2353/ajpath.2008.070851

27. Skrzypczak M, Goryca K, Rubel T, et al. Modeling oncogenic signaling in colon tumors by multidimensional analyses of microarray data directed for maximization of analytical reliability. *PLoS One.* 2010;5(10). doi:10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca

28. Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. *Genome Biol.* 2007;8(7):R131. doi:10.1186/gb-2007-8-7-r11

29. Hong Y, Downey T, Eu KW, et al. A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. *Clin Exp Metastasis.* 2010;27(2):83–90. doi:10.1007/s10585-010-9305-4

30. Budinska E, Popovici V, Teijar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. *J Pathol.* 2013;231(1):63–76. doi:10.1002/path.4212

31. Gundert M, Edelmann D, Benner A, et al. Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier). *Gut.* 2019;68:101–110.
Supplementary materials

Figure S1 Gene set enrichment analysis (GSEA) enrichment analysis of the co-expressed genes. Notes: (A) GSEA-generated heatmap for highly enriched genes in extracellular matrix (ECM) receptor interaction and the Toll-like receptor (TLR) signaling pathway on APOC1-higher expression group compared to the APOC1-lower expression group from the TCGA COAD-READ dataset. (B) GSEA on the TCGA COAD-READ dataset identified ECM receptor interaction and the TLR signaling pathway as regulatory targets of APOC1. The GSEA enrichment plot shows values for normalized enrichment score (NES) = 2.00, NES = 1.91 and P < 0.001, P = 0.002.

Table S1 Small interfering RNA (siRNA) sequences that target apolipoprotein C1 (si-APOC1) and negative control siRNA (si-Control)

| siRNA        | Sense sequence (5’-3’)               | Antisense sequence (5’-3’)               |
|--------------|--------------------------------------|------------------------------------------|
| si-APOC1 #1  | GAAACACACTGGAGGACAA                  | CUUUGUGUGACCUCCUGU                       |
| si-APOC1 #2  | ATTTCGGTGACTTCCGCATC                 | UAAAGCCACUGAAGGCCGAG                     |
| si-APOC1 #3  | TGGGACACAGGCAAGTTCTTCT               | ACCCGUGUGUGCGGCUACA                      |
| si-Control   | UUCUCCGGAACGUGUCAGU                  | AAGAGCGUUGCAACAGAGCA                     |

Table S2 PCR primers for APOC1 and downstream target genes

| Gene          | Sequence                  |
|---------------|---------------------------|
| GAPDH-F       | CGCTGAGTGCTGGAGTC         |
| GAPDH-R       | GCTGATCTTGGAGGCTGGTGC    |
| APOC1-F       | ACCCACTTTAAGATTGGAGGCCC  |
| APOC1-R       | CAGACCACCTAGTCCCCTTCC    |
Table S3  Cox regression analysis of potential diseases free survival factors for patients with colorectal cancer

| Variable                  | Univariate analysis               | Multivariate analysis        |
|---------------------------|-----------------------------------|------------------------------|
|                           | HR (95% CI)                       | p-Value                      | HR (95% CI)                      | p-Value |
| Age (years)               | 0.747 (0.459 to 1.215)            | 0.240                        | 0.240                            | 0.311   |
| Gender                    | 1.378 (0.845 to 2.249)            | 0.199                        | 0.199                            | 0.311   |
| Tumor location            | 1.084 (0.927 to 1.269)            | 0.311                        | 0.311                            | 0.311   |
| Tumor size                |                                   |                              |                                   |         |
| <5 cm                     | 0.611 (0.373 to 1.002)            | 0.051                        | 0.051                            |         |
| ≥5 cm                     | 1.000                             |                               | 1.000                            |         |
| TNM stage                 |                                   |                              |                                   |         |
| I                         | 0.098 (0.032 to 0.294)            | <0.001*                      | 0.111 (0.036 to 0.339)           | <0.001* |
| II                        | 0.204 (0.105 to 0.398)            | <0.001*                      | 0.218 (0.111 to 0.426)           | <0.001* |
| III                       | 0.376 (0.200 to 0.710)            | 0.003*                       | 0.390 (0.206 to 0.737)           | 0.004*  |
| IV                        | 1.000                             |                               | 1.000                            |         |
| APOC1 expression          |                                   |                              |                                   |         |
| High                      | 1.803 (1.101 to 2.955)            | 0.019*                       | 1.450 (0.877 to 2.396)           | 0.147   |
| Low                       | 1.000                             |                               | 1.000                            |         |

Notes: The TNM staging system is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N) and the presence of metastasis (M). *Statistically significant.